Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089939 | 0.75 | MEN1 (0.37) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL22686144 | 0.74 | PDE3B (0.45) | MEN1ALDH1A1KMT2A | |
| SCHEMBL22717184 | 0.74 | EHMT2 (0.37) | — | |
| SCHEMBL22717228 | 0.72 | NNMT (0.35) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL22699619 | 0.71 | MEN1 (0.34) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL21055860 | 0.71 | GRM5 (0.41) | ALDH1A1GAA | |
| SCHEMBL22717074 | 0.71 | EHMT2 (0.33) | MEN1KMT2A | |
| SCHEMBL910059 | 0.67 | MEN1 (0.53) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL1367372 | 0.67 | MEN1 (0.58) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL9322559 | 0.67 | ACHE (0.42) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | claimed |
| EP-3720495-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | Angex Pharmaceutical, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| WO-2019112719-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. (US) | 2019-06-13 | — | — | WO | claimed |
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | disclosed |
| EP-3720495-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | Angex Pharmaceutical, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| WO-2019112719-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | MEN1 1386/4885ALDH1A1 4188/4885GAA 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.